Athersys Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Athersys Inc (ATHX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Athersys Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 5M vs 1,736M combined for tracked competitors (0.3% combined share).
- Peer differentiation: Revenue per employee of $0.12M compares with $0.39M for the peer group (0.3x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
Athersys Inc vs. its Competitors, Q3 2023
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Athersys Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Athersys Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Athersys Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (3) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Athersys Inc's competitor groups requires a Commercial License.
Athersys Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Athersys Inc | - | - | - | Yes |
| Competitors combined (81) | ||||
| High-Confidence Competitors (3) | - |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ATHX Stock Performance relative to its Competitors
ATHX Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Nuvectis Pharma inc | 282.9% | Outperformed |
| 2 | Immix Biopharma Inc | 282.9% | Outperformed |
| 3 | Merus N v | 282.9% | Outperformed |
| 4 | Longeveron Inc | 282.9% | Outperformed |
| 5 | Boundless Bio Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Athersys Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Athersys Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Athersys Inc | 0.00 | 5.33 |
| Cerevel Therapeutics Holdings Inc | 8,165.22 | 0.00 |
| Praxis Precision Medicines Inc | 7,797.30 | 8.55 |
| Merus N v | 6,810.81 | 56.61 |
| Marizyme Inc | 4,922.16 | 0.65 |
| Kazia Therapeutics Limited | 4,424.63 | 0.03 |
| SUBTOTAL | 44,186.43 | 1,840.34 |
Sign in to see all competitors of Athersys Inc.
Sources: Athersys Inc's official press releases and company reports; CSIMarket.com's market research; and the company reports and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Athersys Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Athersys Inc's Competitors Named by the Company
Competitive relationships identified from Athersys Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Creative Medical Technology Holdings Inc | Company report | 85% |
| Harvard Apparatus Regenerative Technology Inc | Company report | 85% |
| Quoin Pharmaceuticals Ltd | Company report | 85% |
| Brainstorm Cell Therapeutics inc | Company report | 85% |
| Biorestorative Therapies Inc | Company report | 85% |
| Fate Therapeutics Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Athersys Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from Athersys Inc reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.
Athersys Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Verastem Inc | Research Developing and Commercialization Drugs Segment 100.00 % |
| Geron Corporation | Reportable 99.93 % |
| Ardelyx inc | Reportable 100.00 % |
| 2seventy Bio Inc | Reportable 100.00 % |
| Harvard Apparatus Regenerative Technology Inc | Consumer Health Products 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Athersys Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Athersys Inc | 0 | 123,837 | -872,256 |
| Cerevel Therapeutics Holdings Inc | 8,165 | 0 | -1,771,031 |
| Praxis Precision Medicines Inc | 7,797 | 50,911 | -2,018,607 |
| Merus N v | 6,811 | 539,105 | -3,629,857 |
| Marizyme Inc | 4,922 | - | - |
| Kazia Therapeutics Limited | 4,425 | 579 | -285,369 |
| PEERS TOTAL | 44,186 | 391,931 | -694,903 |
Athersys Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Durect Corp | Europe 72.48 % |
| Vycor Medical Inc | US 99.66 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Athersys Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (457 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.1x | - |
| EV / EBITDA | - | 15.9x | - |
| P/B | 0.0x | 4.3x | -4.3x |
| Return on Equity | 116.59 % | industry aggregate | 105.13 % |
| Return on Invested Capital | 65.16 % | -4.06 % (avg) | 69.22 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Athersys Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2014 | 2015 | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | 500.00 % | 45.19 % | -83.76 % | -76.82 % | - | - | - |
| Operating Margin | -1,787.55 % | -143.71 % | -86.62 % | -806.21 % | -807.53 % | - | - | - |
| Return on Invested Capital | -47.91 % | -42.72 % | - | -78.11 % | -69.60 % | -92.42 % | -124.59 % | 408.55 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Athersys Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 105.1 points above the industry aggregate.
Weaknesses
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (57.50 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-56.7% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Athersys Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Athersys Inc | 0.09 | 0.17 | - |
| Cerevel Therapeutics Holdings Inc | 3.33 | 10.31 | 0.91 |
| Praxis Precision Medicines Inc | 11.53 | 11.58 | - |
| Merus N v | 3.67 | 7.20 | - |
| Marizyme Inc | 0.00 | 0.03 | - |
| Kazia Therapeutics Limited | 0.31 | 0.35 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Athersys Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Athersys Inc | Q3 2023 | - | - |
| Cerevel Therapeutics Holdings Inc | Q1 2024 | - | - |
| Praxis Precision Medicines Inc | Q2 2026 | - | - |
| Merus N v | Q3 2025 | +3.2 % | - |
| Marizyme Inc | Q3 2024 | - | - |
| Kazia Therapeutics Limited | Q2 2025 | -98.2 % | - |
| PEERS TOTAL | +42.2 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Athersys Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Athersys Inc | Q3 2023 | - | - |
| Cerevel Therapeutics Holdings Inc | Q1 2024 | - | -19.3 % |
| Praxis Precision Medicines Inc | Q2 2026 | - | +1,717.9 % |
| Merus N v | Q3 2025 | - | +21.0 % |
| Marizyme Inc | Q3 2024 | - | - |
| Kazia Therapeutics Limited | Q2 2025 | - | - |
Athersys Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Athersys Inc | - | - | - |
| Cerevel Therapeutics Holdings Inc | - | - | - |
| Praxis Precision Medicines Inc | - | - | - |
| Merus N v | - | - | - |
| Marizyme Inc | - | - | - |
| Kazia Therapeutics Limited | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Athersys Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Athersys Inc | - | 0.00 |
| Cerevel Therapeutics Holdings Inc | - | - |
| Praxis Precision Medicines Inc | - | 911.65 |
| Merus N v | - | 120.32 |
| Marizyme Inc | - | 7,621.68 |
| Kazia Therapeutics Limited | - | 162,605.63 |
| PEERS AVERAGE | - | 24.01 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.